Cannabinoid-drug interactions vary across brain tumor cell lines
Interactions of ACEA and WIN 55,212-2 mesylate with temozolomide and cisplatin in neuroblastoma and glioblastoma cell lines: an isobolographic analysis.
AI Summary
This cell-study asked whether two cannabinoid-receptor agonists—ACEA, which selectively activates CB1 receptors, and WIN 55,212-2, which activates CB1 and CB2 receptors—could slow growth in neuroblastoma and glioblastoma cell lines, alone or combined with the chemotherapy drugs cisplatin and temozolomide. Researchers used MTT, LDH, and BrdU assays, along with isobolographic analysis, to assess cell viability and drug interactions across five cell lines: CHP-134, KELLY, U-87MG, T98G, and C6. Both cannabinoid agonists showed anti-proliferative effects in these laboratory models, with reported selectivity-index ranges of 2.61–5.95 for ACEA and 4.32–12.85 for WIN 55,212-2.
The combination results were mixed and depended on the cell line and chemotherapy drug. WIN 55,212-2 combined with cisplatin produced a synergistic interaction only in the CHP-134 neuroblastoma line and additive interactions in the other tested lines. Combinations with temozolomide were additive in some models but antagonistic in others, meaning the combination reduced the anti-viability effect; the authors therefore identified those combinations as unsuitable for clinical use based on these tests. Blocking CB1 receptors reduced the cannabinoid agonists’ effects in the two examined cell lines, supporting CB1 involvement, while changes in Bax and Bcl-2 were not detected as the mechanism. This is an abstract-based summary of cell-line research, not a human clinical trial; it cannot establish safety, effectiveness, appropriate dosing, or benefit for people with brain tumors.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Cancer research papers you might find interesting.
Canine tumours show varied CB1 and CB2 expression; treatment effects remain…
A planned pilot trial will test cannabis gummy feasibility for cancer-related…
A meta-analysis finds mixed evidence, not proof cannabis changes oral cancer…
Explore More Research
Stay informed about the latest cannabis science.